99 related articles for article (PubMed ID: 7944307)
1. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy.
Campos Y; Arenas J
Ann Neurol; 1994 Oct; 36(4):680-1. PubMed ID: 7944307
[No Abstract] [Full Text] [Related]
2. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage.
Dalakas MC; Leon-Monzon ME; Bernardini I; Gahl WA; Jay CA
Ann Neurol; 1994 Apr; 35(4):482-7. PubMed ID: 8154877
[TBL] [Abstract][Full Text] [Related]
3. Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy.
Campos Y; Huertas R; Bautista J; Gutiérrez E; Aparicio M; Lorenzo G; Segura D; Villanueva M; Cabello A; Alesso L
Muscle Nerve; 1993 Jul; 16(7):778-81. PubMed ID: 8505934
[TBL] [Abstract][Full Text] [Related]
4. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.
Semino-Mora MC; Leon-Monzon ME; Dalakas MC
Lab Invest; 1994 Jul; 71(1):102-12. PubMed ID: 7518879
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
Chariot P; Monnet I; Gherardi R
Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine-associated myopathy.
Paradis J; Calis KA
Am J Hosp Pharm; 1994 Dec; 51(24):3026-8. PubMed ID: 7856620
[No Abstract] [Full Text] [Related]
8. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.
Lebrecht D; Deveaud C; Beauvoit B; Bonnet J; Kirschner J; Walker UA
Arthritis Rheum; 2008 Jan; 58(1):318-26. PubMed ID: 18163507
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
[TBL] [Abstract][Full Text] [Related]
10. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy.
Campos Y; Huertas R; Lorenzo G; Bautista J; Gutiérrez E; Aparicio M; Alesso L; Arenas J
Muscle Nerve; 1993 Feb; 16(2):150-3. PubMed ID: 8429838
[TBL] [Abstract][Full Text] [Related]
11. Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers.
Gherardi RK; Florea-Strat A; Fromont G; Poron F; Sabourin JC; Authier J
Ann Neurol; 1994 Nov; 36(5):752-8. PubMed ID: 7979221
[TBL] [Abstract][Full Text] [Related]
12. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease?
Le Bras P; D'Oiron R; Quertainmont Y; Halfon P; Caquet R
AIDS; 1994 May; 8(5):716-7. PubMed ID: 8060560
[No Abstract] [Full Text] [Related]
13. HIV or zidovudine myopathy?
Grau JM; Casademont J
Neurology; 1994 Feb; 44(2):361; author reply 362-4. PubMed ID: 8309595
[No Abstract] [Full Text] [Related]
14. [Carnitine deficiency myopathy (author's transl)].
Jerusalem F; Engel AG; Sengupta C; Imbach P; Lämmli J
Dtsch Med Wochenschr; 1980 Apr; 105(14):469-73. PubMed ID: 7363806
[TBL] [Abstract][Full Text] [Related]
15. AZT-induced mitochondrial myopathy.
Tomelleri G; Tonin P; Spadaro M; Tilia G; Orrico D; Barelli A; Bonetti B; Monaco S; Salviati A; Morocutti C
Ital J Neurol Sci; 1992 Dec; 13(9):723-8. PubMed ID: 1336487
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.
Masini A; Scotti C; Calligaro A; Cazzalini O; Stivala LA; Bianchi L; Giovannini F; Ceccarelli D; Muscatello U; Tomasi A; Vannini V
J Neurol Sci; 1999 Jul; 166(2):131-40. PubMed ID: 10475107
[TBL] [Abstract][Full Text] [Related]
17. HIV or zidovudine myopathy?
Gherardi R; Chariot P
Neurology; 1994 Feb; 44(2):361-2; author reply 362-4. PubMed ID: 8309597
[No Abstract] [Full Text] [Related]
18. Cytochrome c oxidase deficiency in zidovudine myopathy affects perifascicular muscle fibres and arterial smooth muscle cells.
Chariot P; Le Maguet F; Authier FJ; Labes D; Poron F; Gherardi R
Neuropathol Appl Neurobiol; 1995 Dec; 21(6):540-7. PubMed ID: 8745244
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy.
Scruggs ER; Dirks Naylor AJ
Pharmacology; 2008; 82(2):83-8. PubMed ID: 18504416
[TBL] [Abstract][Full Text] [Related]
20. Clinical, histological and molecular reversibility of zidovudine myopathy.
Masanés F; Barrientos A; Cebrián M; Pedrol E; Miró O; Casademont J; Grau JM
J Neurol Sci; 1998 Aug; 159(2):226-8. PubMed ID: 9741412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
